The relationship of circulating relaxin‐2 concentrations with short‐term prognosis in patients with acute heart failure: the RELAHF study

H3 relaxin protects against calcium oxalate crystal‐induced renal inflammatory pyroptosis

“…Relaxin‐3 has also received some interest, and we confirmed the anti‐inflammatory and antioxidative effects of synthetic relaxin‐3 (H3 relaxin) in diabetic cardiomyopathy, 11,25 but its role in renal inflammation has not been explored. Notably, clinical studies have reported increased endogenous serum relaxin levels in some patients with chronic diseases, which suggests its involvement in self‐protective mechanisms and its potential as a biomarker of pathological severity and prognosis 26,27 . We therefore hypothesized that the serum relaxin‐3 level differs in patients with CaOx stones.…”

“…Notably, clinical studies have reported increased endogenous serum relaxin levels in some patients with chronic diseases, which suggests its involvement in self-protective mechanisms and its potential as a biomarker of pathological severity and prognosis. 26,27 We therefore hypothesized that the serum relaxin-3 level differs in patients with CaOx stones. This investigation constitutes the first exploration of the existence of inflammatory pyroptosis in CaOx crystal-related renal injury, and this exploration includes various analyses, ranging from phenotypic to mechanistic studies.…”